<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707573</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0003</org_study_id>
    <nct_id>NCT04707573</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4</brief_title>
  <official_title>A Phase 2A Single Dose, Open Label Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability&#xD;
      in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose&#xD;
      of vadadustat.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2010</start_date>
  <completion_date type="Actual">September 24, 2010</completion_date>
  <primary_completion_date type="Actual">September 24, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory parameter values</measure>
    <time_frame>up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign values</measure>
    <time_frame>up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in PR interval, QT interval, QRS interval, and QT corrected (QTc) interval</measure>
    <time_frame>Baseline; Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in heart rate</measure>
    <time_frame>Baseline; Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination findings</measure>
    <time_frame>up to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t½)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to time tau over a dosing interval (AUC[0-τ])</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity (AUC[0-∞])</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (CL/F)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vd/F)</measure>
    <time_frame>prior to dosing; 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post dosing (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in erythropoietin (EPO) at 8, 12, and 24 hours post-dose</measure>
    <time_frame>Baseline; 8, 12, and 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vascular endothelial growth factor (VEGF) at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hepcidin at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in transferrin at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in cystatin-C at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in adiponectin at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ferritin at 24 hours</measure>
    <time_frame>Baseline; 24 hours post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>CKD, Stage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Stage 3 Chronic Kidney Disease (CKD) (Estimated Glomerular Filtration Rate [eGFR] 30 - 59 milliliters [mL]/minute) received a single 500 milligram (mg) oral dose of vadadustat after fasting for at least 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD, Stage 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Stage 4 CKD (eGFR &lt;30 mL/minute and not yet on dialysis) received a single 500 mg oral dose of vadadustat after fasting for at least 4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat</intervention_name>
    <description>oral capsules</description>
    <arm_group_label>CKD, Stage 3</arm_group_label>
    <arm_group_label>CKD, Stage 4</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 79 years of age, inclusive&#xD;
&#xD;
          -  Chronic Kidney Disease Stage 3 (Estimated Glomerular Filtration Rate [eGFR] 30 to 59&#xD;
             milliliters [mL]/minute) or Stage 4 participants (eGFR of &lt;30 mL/minute that were not&#xD;
             yet on dialysis). eGFR was calculated using the Modification of Diet in Renal Disease&#xD;
             (MDRD).&#xD;
&#xD;
          -  Hemoglobin (Hgb) &lt;13.5 grams per deciliter (g/dL) except for Polycystic Kidney Disease&#xD;
             (PKD) participants, in which hemoglobin was to be ≤14 g/dL&#xD;
&#xD;
          -  Transferrin saturation (TSAT) &gt;12% and complete blood count (CBC) indicating&#xD;
             normocytic red blood cell morphology, unless the medical monitor and investigator&#xD;
             agreed that the subject was appropriate for this study&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.8 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤2 x ULN&#xD;
&#xD;
          -  Bilirubin ≤1.5 x ULN&#xD;
&#xD;
          -  Female participants were not pregnant or breast-feeding. Women of childbearing&#xD;
             potential agreed to use an acceptable method of contraception.&#xD;
&#xD;
          -  Non-vasectomized male participants agreed to use an acceptable method of contraception&#xD;
&#xD;
          -  Understood the procedures and requirements of the study and provided written informed&#xD;
             consent and authorization for protected health information disclosure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical or psychological condition that in the opinion of the Investigator would&#xD;
             have interfered with the participant's ability to provide informed consent or comply&#xD;
             with study instructions&#xD;
&#xD;
          -  Any clinically significant or uncontrolled medical condition that in the opinion of&#xD;
             the Investigator would have placed the participant at undo risk or would have&#xD;
             compromised the interpretability of the findings in this study&#xD;
&#xD;
          -  A body mass index (BMI) of greater than 40&#xD;
&#xD;
          -  Seropositive for human immunodeficiency virus (HIV) or Hepatitis B surface antigen&#xD;
&#xD;
          -  Seropositive for Hepatitis C virus (HCV) antibodies unless ALT, AST, bilirubin tests&#xD;
             were within normal limits&#xD;
&#xD;
          -  History of chronic liver disease&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic blood pressure [BP] &gt; 110 millimeters of mercury&#xD;
             [mm Hg] or systolic BP &gt;190 mm Hg at screening)&#xD;
&#xD;
          -  New York Heart Association Class III or IV congestive heart failure&#xD;
&#xD;
          -  Myocardial infarction, acute coronary syndrome, or stroke within 6 months of dosing&#xD;
&#xD;
          -  History of myelodysplastic syndrome&#xD;
&#xD;
          -  Participants known to have diabetic gastroparesis that was either symptomatic on&#xD;
             therapy or was refractory to therapy&#xD;
&#xD;
          -  Any history of malignancy in the previous 5 years except for curatively resected basal&#xD;
             cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ,&#xD;
             or resected benign colonic polyps&#xD;
&#xD;
          -  Evidence of active infection unless the medical monitor and investigator agreed that&#xD;
             the participant was appropriate for this study&#xD;
&#xD;
          -  History of rheumatoid arthritis or systemic lupus erythematosus (SLE) (History of&#xD;
             osteoarthritis or gout did not exclude participants from eligibility in the study.)&#xD;
&#xD;
          -  Age-related macular degeneration (AMD), diabetic macular edema or active diabetic&#xD;
             proliferative retinopathy that was likely to require treatment during the trial&#xD;
&#xD;
          -  History of deep vein thrombosis (DVT) that required active treatment. Superficial&#xD;
             thrombosis was not excluded.&#xD;
&#xD;
          -  History of ongoing hemolysis or diagnosis of hemolytic syndrome&#xD;
&#xD;
          -  Known history of bone marrow fibrosis&#xD;
&#xD;
          -  History of hemosiderosis or hemochromatosis&#xD;
&#xD;
          -  Androgen therapy within 21 days from the last injection&#xD;
&#xD;
          -  Red blood cell transfusion within 12 weeks&#xD;
&#xD;
          -  Therapy with an erythropoiesis stimulating agent (ESA) such as human recombinant&#xD;
             erythropoietin within the past 21 days&#xD;
&#xD;
          -  Intravenous iron supplementation within the past 21 days&#xD;
&#xD;
          -  Currently taking acetaminophen &gt; 2.6 grams/day&#xD;
&#xD;
          -  History of prior organ transplantation, or stem cell or bone marrow transplantation&#xD;
&#xD;
          -  Alcohol consumption greater than 14 or more drinks per week within the past year (1&#xD;
             drink = 12 ounce [oz] beer, 5 oz wine, or 1.5 oz hard liquor.)&#xD;
&#xD;
          -  Use of an investigational medication or participation in an investigational study&#xD;
             within 30 days, or 5 half-lives of the investigational product, whichever was longer,&#xD;
             preceding Day 1&#xD;
&#xD;
          -  Positive urine toxicology screen for a substance of abuse that had not been prescribed&#xD;
             for the participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <disposition_first_submitted>January 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 14, 2021</disposition_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>CKD, Stage 3</keyword>
  <keyword>CKD, Stage 4</keyword>
  <keyword>vadadustat</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

